These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37399489)

  • 1. A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura.
    Falter T; Rossmann H; de Waele L; Dekimpe C; von Auer C; Müller-Calleja N; Häuser F; Degreif A; Marandiuc D; Messmer X; Sprinzl M; Lackner KJ; Jurk K; Vanhoorelbeke K; Lämmle B
    Blood Adv; 2023 Sep; 7(17):5091-5102. PubMed ID: 37399489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U; Schneppenheim R
    Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
    Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
    Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
    Di Pasquale I; Budde U; Tona F; Bertomoro A; Lombardi AM; Famoso G; Bertozzi I; Dittmer R; Schneppenheim S; Fabris F
    Thromb Res; 2019 Jan; 173():42-47. PubMed ID: 30471507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
    Chen M; Shortt J
    Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
    Groot E; Fijnheer R; Sebastian SA; de Groot PG; Lenting PJ
    J Thromb Haemost; 2009 Jun; 7(6):962-9. PubMed ID: 19548905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Long-Term Follow-Up Study in Immune-Mediated Thrombotic Thrombocytopenic Purpura: What Are the Outcomes?
    Bonifacio MA; Roselli D; Schifone CP; Ricco A; Vitucci A; Aprile L; Mariggiò MA; Ranieri P
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
    Sui J; Zheng L; Zheng XL
    Arch Pathol Lab Med; 2023 Aug; 147(8):974-979. PubMed ID: 36223210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
    Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
    Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity.
    Tellier E; Widemann A; Cauchois R; Faccini J; Lagarde M; Brun M; Robert P; Robert S; Bachelier R; Poullin P; Roose E; Vanhoorelbeke K; Coppo P; Dignat-George F; Kaplanski G
    Haematologica; 2023 Apr; 108(4):1127-1140. PubMed ID: 36453103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
    Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
    Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
    Mazepa MA; Park YA; Raval JS
    Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission.
    Lotta LA; Lombardi R; Mariani M; Lancellotti S; De Cristofaro R; Hollestelle MJ; Canciani MT; Mannucci PM; Peyvandi F
    J Thromb Haemost; 2011 Sep; 9(9):1744-51. PubMed ID: 21726405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
    Doevelaar AAN; Bachmann M; Hölzer B; Seibert FS; Rohn BJ; Bauer F; Witzke O; Dittmer U; Bachmann M; Yilmaz S; Dittmer R; Schneppenheim S; Babel N; Budde U; Westhoff TH
    Crit Care Med; 2021 May; 49(5):e512-e520. PubMed ID: 33591004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
    Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
    Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
    Poullin P
    Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
    Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
    Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.